Surrozen Initiates Dosing in Phase I Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. announced that the first subject has been dosed in its three-part Phase I clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.